Biomarker Strategy Planning demo
Each program's biomarkers laid out as lanes across the phases (target engagement, pharmacodynamics, patient selection and safety) with the assay, its readiness and the decision it supports, beside how rival trials use the same markers. 1:15
What the demo shows
A translational medicine solution for program teams that builds a cited biomarker plan.
Every program opens on a strategy map: four lanes (target engagement, pharmacodynamics, patient selection and safety) across the phases, each card showing the assay, when it is ready and the decision it supports. Below it, a field lane shows how rival trials in the same indication use the same markers, read from registries and papers. Six agents gather the evidence, draft the strategy, time the assays against first participant in and cost the options; a biomarker scientist checks the values and the translational board signs.
Transcript
- Biomarker Strategy Planning builds sighted biomarker plans for translational medicine teams.
- By hand, a strategy takes weeks and assay timing stays hidden.
- Here in WB, 3140's biomarkers run as four lanes across the phases.
- Each card shows the assay, its readiness and the decision it supports.
- In patient selection, the PE, TAO 217 prescreen is not ready.
- until Phase 2B. Below, the field lane shows two rivals already enrolling on that same marker.
- One click asks the agent what would bring it forward.
- A second CLI laboratory, ready in March, avoids about 190 PET scans.
- Maya proposes it and the gap, the assay plan, and the strategy update together.
- Built on Botminds: agents, data, screens, and governance on one platform.
Transcribed from the film’s narration. Captions are on the player.